ABBV241101P155000
- 0.01
- 0.000.00%
AbbVie Newsroom
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $212
AbbVie Price Target Raised to $200.00/Share From $195.00 by UBS
AbbVie Is Maintained at Neutral by UBS
Cantor Fitzgerald Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $240
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $231
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $205 to $240
AbbVie Analyst Ratings
Morgan Stanley Raises Price Target on AbbVie to $231 From $218, Keeps Overweight Rating
Evercore ISI Adjusts Price Target on AbbVie to $204 From $192
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie Is Maintained at Buy by Citigroup
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $209
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $206
AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline Uncertainties Warrants Hold Rating
Goldman Sachs Adjusts Price Target on AbbVie to $208 From $200
AbbVie Is Maintained at Neutral by B of A Securities
AbbVie Analyst Ratings
BofA Securities Initiates AbbVie(ABBV.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)